Dyadic International (NASDAQ:DYAI) Shares Cross Below 50-Day Moving Average – Time to Sell?

Dyadic International Inc. (NASDAQ:DYAI)’s share price passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $0.85 and traded as low as $0.7850. Dyadic International shares last traded at $0.8010, with a volume of 22,680 shares trading hands.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Dyadic International in a report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $3.00.

Dyadic International Stock Performance

The company has a quick ratio of 2.85, a current ratio of 2.85 and a debt-to-equity ratio of 1.92. The firm has a 50-day moving average price of $0.85 and a 200 day moving average price of $0.95. The firm has a market capitalization of $27.50 million, a PE ratio of -3.17 and a beta of 1.29.

Institutional Trading of Dyadic International

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Bank of America Corp DE boosted its stake in shares of Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 26,965 shares during the period. Marathon Capital Management purchased a new stake in Dyadic International during the 3rd quarter worth approximately $41,000. Geode Capital Management LLC lifted its holdings in Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after buying an additional 36,266 shares in the last quarter. Chapin Davis Inc. lifted its holdings in Dyadic International by 5.6% during the 3rd quarter. Chapin Davis Inc. now owns 932,004 shares of the biotechnology company’s stock worth $1,100,000 after buying an additional 49,155 shares in the last quarter. Finally, AlphaCore Capital LLC purchased a new position in Dyadic International in the 2nd quarter valued at approximately $50,000. 27.95% of the stock is currently owned by hedge funds and other institutional investors.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.